PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane

PURPOSE: Everolimus plus exemestane (EVE/EXE) is a registered treatment option for ER-positive, HER2-negative (ER +/HER2-) metastatic breast cancer (MBC), but resistance mechanisms limit efficacy. We aimed to find markers that might help select patients with a higher chance on benefit from EVE/EXE....

Descripción completa

Detalles Bibliográficos
Autores principales: Kruger, Dinja T., Opdam, Mark, van der Noort, Vincent, Sanders, Joyce, Nieuwenhuis, Michiel, de Valk, Bart, Beelen, Karin J., Linn, Sabine C., Boven, Epie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519923/
https://www.ncbi.nlm.nih.gov/pubmed/32566979
http://dx.doi.org/10.1007/s00432-020-03291-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519923/
https://www.ncbi.nlm.nih.gov/pubmed/32566979
http://dx.doi.org/10.1007/s00432-020-03291-x

Ejemplares similares